Publications 2018

Publications (original articles or review articles) published in 2018 from OUS - Molecular Medicine (Sioud)

3 publications found

Peng W, de Bruijn HS, Farrell E, Sioud M, Mashayekhi V, Oliveira S, van Dam GM, Roodenburg JLN, Witjes MJH, Robinson DJ (2018)
Epidermal growth factor receptor (EGFR) density may not be the only determinant for the efficacy of EGFR-targeted photoimmunotherapy in human head and neck cancer cell lines
Lasers Surg Med, 50 (5), 513-522
DOI 10.1002/lsm.22930, PubMed 29777587

Sioud M (2018)
T-cell cross-reactivity may explain the large variation in how cancer patients respond to checkpoint inhibitors
Scand J Immunol, 87 (3)
DOI 10.1111/sji.12643, PubMed 29381830

Sioud M, Westby P, Vasovic V, Fløisand Y, Peng Q (2018)
Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies
FASEB J, 32 (9), 5063-5077
DOI 10.1096/fj.201701544R, PubMed 29913558

Publications 2017

Publications (original articles or review articles) published in 2018 from OUS - Molecular Medicine (Sioud)

3 publications found

Peng W, de Bruijn HS, Farrell E, Sioud M, Mashayekhi V, Oliveira S, van Dam GM, Roodenburg JLN, Witjes MJH, Robinson DJ (2018)
Epidermal growth factor receptor (EGFR) density may not be the only determinant for the efficacy of EGFR-targeted photoimmunotherapy in human head and neck cancer cell lines
Lasers Surg Med, 50 (5), 513-522
DOI 10.1002/lsm.22930, PubMed 29777587

Sioud M (2018)
T-cell cross-reactivity may explain the large variation in how cancer patients respond to checkpoint inhibitors
Scand J Immunol, 87 (3)
DOI 10.1111/sji.12643, PubMed 29381830

Sioud M, Westby P, Vasovic V, Fløisand Y, Peng Q (2018)
Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies
FASEB J, 32 (9), 5063-5077
DOI 10.1096/fj.201701544R, PubMed 29913558

Publications 2016

Publications (original articles or review articles) published in 2018 from OUS - Molecular Medicine (Sioud)

3 publications found

Peng W, de Bruijn HS, Farrell E, Sioud M, Mashayekhi V, Oliveira S, van Dam GM, Roodenburg JLN, Witjes MJH, Robinson DJ (2018)
Epidermal growth factor receptor (EGFR) density may not be the only determinant for the efficacy of EGFR-targeted photoimmunotherapy in human head and neck cancer cell lines
Lasers Surg Med, 50 (5), 513-522
DOI 10.1002/lsm.22930, PubMed 29777587

Sioud M (2018)
T-cell cross-reactivity may explain the large variation in how cancer patients respond to checkpoint inhibitors
Scand J Immunol, 87 (3)
DOI 10.1111/sji.12643, PubMed 29381830

Sioud M, Westby P, Vasovic V, Fløisand Y, Peng Q (2018)
Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies
FASEB J, 32 (9), 5063-5077
DOI 10.1096/fj.201701544R, PubMed 29913558

Publications 2015

Publications (original articles or review articles) published in 2018 from OUS - Molecular Medicine (Sioud)

3 publications found

Peng W, de Bruijn HS, Farrell E, Sioud M, Mashayekhi V, Oliveira S, van Dam GM, Roodenburg JLN, Witjes MJH, Robinson DJ (2018)
Epidermal growth factor receptor (EGFR) density may not be the only determinant for the efficacy of EGFR-targeted photoimmunotherapy in human head and neck cancer cell lines
Lasers Surg Med, 50 (5), 513-522
DOI 10.1002/lsm.22930, PubMed 29777587

Sioud M (2018)
T-cell cross-reactivity may explain the large variation in how cancer patients respond to checkpoint inhibitors
Scand J Immunol, 87 (3)
DOI 10.1111/sji.12643, PubMed 29381830

Sioud M, Westby P, Vasovic V, Fløisand Y, Peng Q (2018)
Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies
FASEB J, 32 (9), 5063-5077
DOI 10.1096/fj.201701544R, PubMed 29913558

Publications 2014

Publications (original articles or review articles) published in 2018 from OUS - Molecular Medicine (Sioud)

3 publications found

Peng W, de Bruijn HS, Farrell E, Sioud M, Mashayekhi V, Oliveira S, van Dam GM, Roodenburg JLN, Witjes MJH, Robinson DJ (2018)
Epidermal growth factor receptor (EGFR) density may not be the only determinant for the efficacy of EGFR-targeted photoimmunotherapy in human head and neck cancer cell lines
Lasers Surg Med, 50 (5), 513-522
DOI 10.1002/lsm.22930, PubMed 29777587

Sioud M (2018)
T-cell cross-reactivity may explain the large variation in how cancer patients respond to checkpoint inhibitors
Scand J Immunol, 87 (3)
DOI 10.1111/sji.12643, PubMed 29381830

Sioud M, Westby P, Vasovic V, Fløisand Y, Peng Q (2018)
Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies
FASEB J, 32 (9), 5063-5077
DOI 10.1096/fj.201701544R, PubMed 29913558

Publications 2013

Publications (original articles or review articles) published in 2018 from OUS - Molecular Medicine (Sioud)

3 publications found

Peng W, de Bruijn HS, Farrell E, Sioud M, Mashayekhi V, Oliveira S, van Dam GM, Roodenburg JLN, Witjes MJH, Robinson DJ (2018)
Epidermal growth factor receptor (EGFR) density may not be the only determinant for the efficacy of EGFR-targeted photoimmunotherapy in human head and neck cancer cell lines
Lasers Surg Med, 50 (5), 513-522
DOI 10.1002/lsm.22930, PubMed 29777587

Sioud M (2018)
T-cell cross-reactivity may explain the large variation in how cancer patients respond to checkpoint inhibitors
Scand J Immunol, 87 (3)
DOI 10.1111/sji.12643, PubMed 29381830

Sioud M, Westby P, Vasovic V, Fløisand Y, Peng Q (2018)
Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies
FASEB J, 32 (9), 5063-5077
DOI 10.1096/fj.201701544R, PubMed 29913558

Publications 2012

Publications (original articles or review articles) published in 2018 from OUS - Molecular Medicine (Sioud)

3 publications found

Peng W, de Bruijn HS, Farrell E, Sioud M, Mashayekhi V, Oliveira S, van Dam GM, Roodenburg JLN, Witjes MJH, Robinson DJ (2018)
Epidermal growth factor receptor (EGFR) density may not be the only determinant for the efficacy of EGFR-targeted photoimmunotherapy in human head and neck cancer cell lines
Lasers Surg Med, 50 (5), 513-522
DOI 10.1002/lsm.22930, PubMed 29777587

Sioud M (2018)
T-cell cross-reactivity may explain the large variation in how cancer patients respond to checkpoint inhibitors
Scand J Immunol, 87 (3)
DOI 10.1111/sji.12643, PubMed 29381830

Sioud M, Westby P, Vasovic V, Fløisand Y, Peng Q (2018)
Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies
FASEB J, 32 (9), 5063-5077
DOI 10.1096/fj.201701544R, PubMed 29913558

Publications 2011

Publications (original articles or review articles) published in 2018 from OUS - Molecular Medicine (Sioud)

3 publications found

Peng W, de Bruijn HS, Farrell E, Sioud M, Mashayekhi V, Oliveira S, van Dam GM, Roodenburg JLN, Witjes MJH, Robinson DJ (2018)
Epidermal growth factor receptor (EGFR) density may not be the only determinant for the efficacy of EGFR-targeted photoimmunotherapy in human head and neck cancer cell lines
Lasers Surg Med, 50 (5), 513-522
DOI 10.1002/lsm.22930, PubMed 29777587

Sioud M (2018)
T-cell cross-reactivity may explain the large variation in how cancer patients respond to checkpoint inhibitors
Scand J Immunol, 87 (3)
DOI 10.1111/sji.12643, PubMed 29381830

Sioud M, Westby P, Vasovic V, Fløisand Y, Peng Q (2018)
Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies
FASEB J, 32 (9), 5063-5077
DOI 10.1096/fj.201701544R, PubMed 29913558

Annual summary Institute for Cancer Research

Publications (original articles or review articles) published in 2018 from OUS - Molecular Medicine (Sioud)

3 publications found

Peng W, de Bruijn HS, Farrell E, Sioud M, Mashayekhi V, Oliveira S, van Dam GM, Roodenburg JLN, Witjes MJH, Robinson DJ (2018)
Epidermal growth factor receptor (EGFR) density may not be the only determinant for the efficacy of EGFR-targeted photoimmunotherapy in human head and neck cancer cell lines
Lasers Surg Med, 50 (5), 513-522
DOI 10.1002/lsm.22930, PubMed 29777587

Sioud M (2018)
T-cell cross-reactivity may explain the large variation in how cancer patients respond to checkpoint inhibitors
Scand J Immunol, 87 (3)
DOI 10.1111/sji.12643, PubMed 29381830

Sioud M, Westby P, Vasovic V, Fløisand Y, Peng Q (2018)
Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies
FASEB J, 32 (9), 5063-5077
DOI 10.1096/fj.201701544R, PubMed 29913558

Publications

Publications (original articles or review articles) published in 2018 from OUS - Molecular Medicine (Sioud)

3 publications found

Peng W, de Bruijn HS, Farrell E, Sioud M, Mashayekhi V, Oliveira S, van Dam GM, Roodenburg JLN, Witjes MJH, Robinson DJ (2018)
Epidermal growth factor receptor (EGFR) density may not be the only determinant for the efficacy of EGFR-targeted photoimmunotherapy in human head and neck cancer cell lines
Lasers Surg Med, 50 (5), 513-522
DOI 10.1002/lsm.22930, PubMed 29777587

Sioud M (2018)
T-cell cross-reactivity may explain the large variation in how cancer patients respond to checkpoint inhibitors
Scand J Immunol, 87 (3)
DOI 10.1111/sji.12643, PubMed 29381830

Sioud M, Westby P, Vasovic V, Fløisand Y, Peng Q (2018)
Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies
FASEB J, 32 (9), 5063-5077
DOI 10.1096/fj.201701544R, PubMed 29913558